BioVie (BIVI) AI Stock Analysis

• Market Cap: $9.27M
• Dividend Yield: N/A
• Average Volume (3M): 240.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: N/A
• EPS Growth: 84.44%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.95
• Shares Outstanding: 7,540,316
• 10 Day Avg. Volume: 205,264
• 30 Day Avg. Volume: 240,835
• PEG Ratio: <0.01
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.72
• Enterprise Value/Market Cap: -1.75
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 141.28
• Enterprise Value/Ebitda: 0.87
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: ―

BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors.

Positive Factors

Strong Equity Position

A strong equity position with minimal debt provides financial stability, allowing BioVie to fund R&D activities without immediate pressure from creditors.

Innovative Product Pipeline

BioVie's focus on innovative therapies for unmet medical needs positions it well for future growth, as successful trials could lead to significant market opportunities.

Partnership Opportunities

Strategic partnerships can provide funding and expertise, accelerating product development and commercialization, which is vital for a clinical-stage biotech company.

Negative Factors

High Cash Burn

High cash burn without revenue generation can strain financial resources, necessitating continuous external financing, which may dilute shareholder value over time.

No Revenue Generation

The absence of revenue generation limits financial flexibility and increases reliance on external funding, posing risks if product development timelines extend.

Ongoing Net Losses

Ongoing net losses reflect the challenges of sustaining operations without revenue, highlighting the need for successful product commercialization to achieve profitability.

BioVie Business Overview & Revenue Model

Company Description

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

How the Company Makes Money

BioVie primarily makes money through the development and eventual commercialization of its pharmaceutical products. The company seeks to generate revenue by advancing its drug candidates through clinical trials, obtaining regulatory approvals, and partnering with larger pharmaceutical companies for distribution and marketing. Significant partnerships with research institutions and pharmaceutical firms play a crucial role in funding research and development efforts. Additionally, BioVie may earn revenue through milestone payments and royalties as its products move closer to market availability and achieve commercial success.

BioVie Financial Statement Overview

Summary

BioVie is in the pre-commercialization phase with no revenue generation and high net losses. The company relies heavily on equity financing, as indicated by a strong equity position and minimal debt. However, the ongoing cash burn in R&D activities highlights significant financial risks.

Income Statement

BioVie shows consistent negative gross profit and net income, with no revenue generation, which is typical for early-stage biotech companies. The ongoing net losses and negative EBIT and EBITDA margins indicate a company still in the R&D phase without product commercialization. Growth metrics are not applicable due to zero revenue.

Balance Sheet

The balance sheet reflects a relatively high stockholders' equity and minimal debt, leading to a favorable debt-to-equity ratio. However, the company's equity ratio suggests reliance on equity financing, typical for biotech firms. The improving equity position is a positive sign, but the lack of tangible assets remains a concern.

Cash Flow

BioVie has negative operating and free cash flows, indicative of high cash burn in R&D activities. There is significant reliance on financing cash flows to maintain operations. The lack of positive cash flow metrics highlights the company's current inability to generate cash from operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-114.69K	-229.38K	0.00	0.00	0.00	0.00
EBITDA	-18.66M	-16.98M	-31.95M	-45.73M	-27.02M	-137.82M
Net Income	-18.52M	-17.54M	-32.12M	-50.26M	-26.08M	-130.25M
Balance Sheet
Total Assets	26.82M	21.56M	25.21M	35.10M	20.11M	6.05M
Cash, Cash Equivalents and Short-Term Investments	24.98M	17.54M	23.84M	33.94M	18.64M	4.51M
Total Debt	332.73K	349.89K	6.11M	14.42M	12.26M	0.00
Total Liabilities	1.90M	2.55M	9.70M	19.76M	16.44M	996.37K
Stockholders Equity	24.92M	19.01M	15.51M	15.34M	3.67M	5.05M
Cash Flow
Free Cash Flow	-18.47M	-19.03M	-27.95M	-40.25M	-18.99M	-10.45M
Operating Cash Flow	-18.47M	-19.03M	-27.95M	-40.25M	-18.99M	-10.45M
Investing Cash Flow	0.00	0.00	14.53M	-14.30M	0.00	0.00
Financing Cash Flow	23.42M	12.73M	17.80M	55.37M	33.12M	14.93M

BioVie Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIVI, the sentiment is Negative. The current price of 1.24 is below the 20-day moving average (MA) of 1.25, below the 50-day MA of 1.35, and below the 200-day MA of 4.63, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 45.30 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIVI.

BioVie Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LPCN	54 Neutral	$52.52M	-8.85	-32.92%	―	-44.31%	-34.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EDSA	50 Neutral	$11.17M	-0.91	-99.57%	―	―	30.29%
CING	47 Neutral	$44.01M	-1.08	-284.50%	―	―	93.84%
CANF	41 Neutral	$5.96M	―	―	―	―	―
BIVI	38 Underperform	$9.27M	-0.14	-94.79%	―	―	84.44%

BioVie Corporate Events

BioVie Stockholders Approve Key Proposals at Annual Meeting

On November 10, 2025, BioVie Inc. held its annual meeting of stockholders, where several key proposals were considered. Stockholders elected the company’s nominees for director for one-year terms, ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, and approved an amendment to the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance.

The most recent analyst rating on (BIVI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on BioVie stock, see the BIVI Stock Forecast page.